Current biomarkers of canine mammary tumors.

Current biomarkers of canine mammary tumors.
复制标题

DOI:
10.1186/s13028-018-0417-1
复制
发表时间:
2018-10-29
影响因子:
2.1
通讯作者:
Jurka P
Jurka P
中科院分区:
农林科学3区
文献类型:
--
作者:
Kaszak I;Ruszczak A;Kanafa S;Kacprzak K;Król M;Jurka P

文献摘要

参考文献

被引文献

相似文献

乳腺肿瘤是犬中第二常见的肿瘤。由于犬乳腺肿瘤(CMT)与人乳腺癌(HBC)的高度相似性,在CMT病例中也可检测到HBC的人生物标志物。生物标志物的评价使得患有这种疾病的母犬能够进行临床诊断、治疗选择和预后。本文的目的是根据现有文献对CMT的生物标志物进行简要总结。非常有前途的生物标志物是miRNA、癌症干细胞和循环肿瘤细胞,以及乳腺癌1基因(BRCA 1)和乳腺癌2基因(BRCA 2)的突变。迄今为止,研究最多且最可靠的CMT生物标志物仍然是抗原Ki-67(Ki-67)、内皮生长因子受体、人表皮生长因子受体2(HER-2)、雌激素受体、孕激素受体和环氧合酶1(考克斯-2),其可以使用不同的分子方法在血清和组织样品中检测。然而,癌胚抗原和癌抗原15-3(CA 15-3),虽然研究不足,似乎是很好的生物标志物,特别是对CMT的早期检测和预后。我们还将提及以下:增殖细胞核抗原、肿瘤蛋白p53(p53)、E-钙粘蛋白、血管内皮生长因子、microRNA、癌症干细胞和循环肿瘤细胞,它们也可以是有用的生物标志物。尽管目前已经进行了许多研究,但CMT病例中生物标志物的估计仍然不是一种常见的做法,需要进行更详细的研究。
Mammary tumors are the second most common neoplasia in dogs. Due to the high similarity of canine mammary tumors (CMT) to human breast cancers (HBC), human biomarkers of HBC are also detectable in cases of CMT. The evaluation of biomarkers enables clinical diagnoses, treatment options and prognosis for bitches suffering from this disease. The aim of this article is to give a short summary of the biomarkers of CMT based on current literature. Very promising biomarkers are miRNAs, cancer stem cells, and circulating tumor cells, as well as mutations of the breast cancer 1 gene (BRCA1) and breast cancer 2 gene (BRCA2). Until now, the most studied and reliable biomarkers of CMT have remained antigen Ki-67 (Ki-67), endothelial growth factor receptor, human epidermal growth factor receptor 2 (HER-2), estrogen receptor, progesterone receptor and cyclooxygenase 1 (COX-2), which can be detected in both serum and tissue samples using different molecular methods. However, carcinoembryonic antigen and cancer antigen 15-3 (CA 15-3), while poorly studied, seem to be good biomarkers, especially for the early detection and prognosis of CMT. We will also mention the following: proliferative cell nuclear antigen, tumor protein p53 (p53), E-cadherin, vascular endothelial growth factor, microRNAs, cancer stem cells and circulating tumor cells, which can also be useful biomarkers. Although many studies have been conducted so far, the estimation of biomarkers in cases of CMT is still not a common practice, and more detailed research should be done.
DOI: 10.1155/2016/8909878
发表时间: 2016
影响因子: --
作者:
Caceres S;Peña L;Silvan G;Illera MJ;Woodward WA;Reuben JM;Illera JC
通讯作者: Illera JC
DOI: 10.1007/s13277-015-3661-2
发表时间: 2015-11-01
期刊: TUMOR BIOLOGY
影响因子: --
作者:
Burrai, G. P.;Tanca, A.;Antuofermo, E.
通讯作者: Antuofermo, E.
DOI: 10.1354/vp.42-2-200
发表时间: 2005-03-01
影响因子: 2.4
作者:
de las Mulas, JM;Millán, Y;Dios, R
通讯作者: Dios, R
DOI: 10.2460/javma.235.4.391
发表时间: 2009-08-15
影响因子: 1.9
作者:
Chang, Chao-Chin;Tsai, Min-Hsuan;Chang, Shih-Chieh
通讯作者: Chang, Shih-Chieh
DOI: 10.1186/s12885-017-3751-1
发表时间: 2017-11-07
期刊: BMC cancer
影响因子: 3.8
作者:
Bulkowska M;Rybicka A;Senses KM;Ulewicz K;Witt K;Szymanska J;Taciak B;Klopfleisch R;Hellmén E;Dolka I;Gure AO;Mucha J;Mikow M;Gizinski S;Krol M
通讯作者: Krol M